SAB Biotherapeutics (SABS) Projected to Post Earnings on Thursday

SAB Biotherapeutics (NASDAQ:SABS) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($1.16) per share and revenue of $0.12 million for the quarter.

SAB Biotherapeutics Price Performance

NASDAQ SABS opened at $1.62 on Wednesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.69 and a quick ratio of 3.69. The company has a 50 day simple moving average of $2.15 and a 200-day simple moving average of $2.86. SAB Biotherapeutics has a 52-week low of $1.45 and a 52-week high of $5.01.

Analyst Ratings Changes

A number of equities research analysts have issued reports on SABS shares. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of SAB Biotherapeutics in a research note on Wednesday, January 29th. Chardan Capital reissued a “buy” rating and set a $25.00 price objective on shares of SAB Biotherapeutics in a research report on Wednesday, January 29th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $12.40.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.